Transpire Bio Inc. Appoints Ewan Livesey As New Head Of Business Development To Strengthen Strategic Growth Efforts

Transpire Bio Inc., a U.S.-based clinical-stage and revenue-generating biopharmaceutical company developing inhaled therapies for pulmonary and systemic diseases, announced the appointment of Ewan Livesey as the company’s new Head of Business Development.

According to Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio, the company is steadily advancing its pipeline of complex generics and innovative inhaled medicines. As part of this progress, Transpire Bio is enhancing its business development capabilities to support new in-licensing, out-licensing, and co-development opportunities that align with its long-term strategy. Dr. Zeng emphasized that Mr. Livesey’s appointment brings substantial expertise in all aspects of business development, making him a valuable addition to the leadership team.

Mr. Livesey brings more than three decades of experience in the pharmaceutical and life sciences industries, where he has specialized in corporate and business development. Throughout his career, he has contributed to transformational growth by shaping corporate development strategies and leading major licensing and M&A initiatives. 

His background includes significant leadership positions such as Chief Corporate Development Officer at Rosemont Pharmaceuticals Limited, Chief Business Development Officer at Norgine a.s., Head of Corporate Development at Zentiva Group a.s., and Chief Business Officer at Apotex Inc. He has also held roles in mergers and acquisitions at Lupin Limited, Glenmark Pharmaceuticals Europe, and IVAX Corporation. Earlier in his career, he practiced as a solicitor in the U.K., focusing on corporate matters, intellectual property, and patent litigation in both law firms and in-house legal departments.

Speaking about his new role, Mr. Livesey expressed enthusiasm for joining Transpire Bio during a period of growing momentum. He noted that he looks forward to supporting the company’s strategic partnerships and contributing to the continued progress of its expanding pipeline of inhaled therapeutics. He added that the opportunity to help drive the next phase of the company’s growth makes this role particularly meaningful.

With this appointment, Transpire Bio continues to build its internal capabilities as it advances its mission of developing impactful inhaled therapies for patients and expanding collaboration opportunities across the industry.